Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood

Purpose: The aim of this study was to evaluate the long-term effects of combination chemotherapy treatment for girls with Hodgkin's lymphoma ( HL) on gonadal function using anti-Mullerian hormone ( AMH) and inhibin B as ovarian reserve parameters. Patients and Methods: LH, FSH, inhibin B, and AMH were measured in 32 women treated from 1974 to 1998 for pediatric HL with chemotherapy, with the intention to avoid radiotherapy. All patients [ median age 25.0 yr ( range 19.2-40.4 yr)] were in complete remission with a median follow-up time of 14.0 yr ( range 5.7-24.5 yr) after therapy. All patients were treated with combination chemotherapy doxorubicin, bleomycin, vinblastine and dacarbazine ( ABVD) or EBVD with or without mechlorethamine, vincristine, procarbazine, and prednisone ( MOPP). Because of incomplete remission or relapse, involved field radiotherapy was needed in seven of 32 women. Results were compared with a healthy control group. Results: Patients treated with six or more cycles of MOPP combination chemotherapy had significantly higher levels of FSH and lower serum levels of inhibin B and AMH, compared with healthy women [ FSH, 17.0 vs. 6.0 U/liter ( P